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Clinical practice developed to promote psychosexual well-being in DSD is under scrutiny. Although techniques for genital surgery
have much improved lately, long-term studies on psychosexual functioning and cosmetic outcome on which to base treatment
and counseling are scarce. We studied 91 women with a DSD. Feminizing surgery was performed in 64% of the women; in 60%
of them, resurgery in puberty was needed after a single-stage procedure. Both patients and gynecologists were satisfied with the
cosmetic appearance of the genitalia. However, forty percent of these females experienced sexuality-related distress and 66% was
at risk for developing a sexual dysfunction, whether they had surgery or not. Recognizing the diﬃculty of accurate assessment,
our data indicate that feminizing surgery does not seem to improve nor hamper psychosexual outcome, especially in patients with
severe virilization.
1. Introduction
Disruption of genetic pathways involving a complex network
of genes in the developing embryo may lead to disorders
of sex development (DSD). These are congenital conditions
with atypical development of chromosomal, anatomical, or
gonadal sex [1]. Depending on the diagnosis in infants with
a female gender assignment, medical corrective measures can
include hormone replacement therapy and the removal of
gonads in addition to surgical adjustment of the external
genitalia. Genital surgery can range from the construction
of a vagina or enlarging of the vaginal opening, to clitoris
reduction, and adjustment of the labia [2]. The primary
aim of surgery is to provide a female appearance of the
(masculinized) genitalia and enabling tampon use and sexual
intercourse later in adulthood. In a minority of patients,
it is indicated to promote bladder emptying and to avoid
urological infections.
The medical and psychological management of DSD has
long been interrelated, since medical interventions have
attempted to promote “successful” psychological adjustment
to the established sex and corresponding gender [3]. It is
presumed that “normalizing” the bodies of individuals with
a DSD will be beneficial for psychosocial development and
will avoid stigmatization. Advances in medical knowledge
and understanding of psychosexual development, together
with an increased emphasis on the rights of the individual
and changing attitude towards gender, have all contributed
recently to the debate about this “success” and eﬃcacy of
medical intervention [4]. The advent of well-organized sup-
port groups has given patients the confidence to express their
concerns, and there is increasing evidence of dissatisfaction
with surgery [5], relating to both the timing and outcome
following surgery [6–12]. Genital surgery may have created
sexual dysfunctions (including altered genital sensation)
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Table 1: Patient population.
Virilization degree
Total
46
XY/Chrom
DSD NF
46
XY/Chrom
DSD AG
46 XX DSD
AG
CAH SW 0 0 32 32
CAH SV 0 0 8 8
Undervirilization-Some androgen action1 0 13 0 13
DSD group Undervirilization-CAIS 19 0 0 19
Gonadal dysgenesis-46, XY 7 0 0 7
Gonadal dysgenesis-chromosomal 4 8 0 12
Total 30 21 40 91
1Partial androgen insensitivity syndrome (PAIS) [5], 17β3 hydroxysteroid dehydrogenase deficiency (17β3 HSD) [5], Leydig cell hypoplasia [2], 17, 20 lyase
deficiency [1].
Table 2: Number of clitoroplasties and vaginoplasties performed in the diﬀerent etiological groups.
Clitoroplasty Vaginoplasty No surgery
46 XX DSD AG 37 32 4
CAH-SW 30 29 1
CAH-SV 5 3 3
46 XY/Chrom DSD NF 2 7 23
46 XY GD 2 3 4
Chromosomal GD 0 0 4
No androgen action (CAIS) 0 4 15
46 XY/Chrom DSD AG 10 11 6
Some androgen action 4 6 4
Chromosomal GD 6 5 2
and/or dissatisfaction with cosmetic outcomes [5, 13]. It can
be questioned that the very approach that was adopted to
prevent psychological maladjustment to DSD is in fact the
cause of the high levels of psychological and sexual distress
reported [14].
While some surgeons are recommending greater caution
with the surgical approach [15] and critics point out that
the current treatment practice exposes individuals with DSD
to multiple traumatization [9], others remain convinced
that children would benefit from having genital surgery,
particularly girls with congenital adrenal hyperplasia [3].
This study was undertaken to inform the debate about
the role of genital surgery in the treatment of DSD and to
create a better understanding of the factors that support psy-
chosexual adjustment across the lifespan. Our objective was
to evaluate the influence of genital surgery on psychosexual
and cosmetic outcome in association with the specific DSD
etiology and degree of virilization at birth, for adjusting our
clinical services accordingly to provide the best possible care.
2. Methods
2.1. Procedure and Patients. The study was conducted as a
long-term follow-up audit of DSD patients referred to
Erasmus Medical Centre Rotterdam or Radboud University
Nijmegen Medical Center, the Netherlands, between the
years 2007–2010. 412 patients with a DSD were identified
from the hospital databases. After exclusion, 176 eligible
participants were contacted, inviting them to attend a
clinical visit with a gynecologist and psychologist. Exclusion
criteria were age younger than 14 years and over 60
years, intellectual disability, recent diagnosis (<6 months),
a diagnosis of Mayer-Rokitansky-Ku¨ster-Hauser (MRKH),
Turner syndrome or Klinefelter syndrome, and anatomical
anomalies of the abdomen not related to a deviant gonadal
development such as cloacal malformations. 91 patients
(52%) participated. Patient population, diagnosis informa-
tion, and details of the received surgical treatments are
summarized in Tables 1 and 2. Diagnostic subgroups were
classified according to the consensus statement classification
[1]. The median age was 26 years (range 14–48). All patients
gave written informed consent, and the study was approved
by the medical ethics committee of both institutions.
2.2. Assessments
2.2.1. Gynecological Assessment. The gynecological workup
consisted of a (1) medical-somatic history and (2) a gyne-
cological exam: visual inspection (clitoral size, labia majora,
labia minora, pigmentation, meatus externus urethrae, hair
ISRN Endocrinology 3
growth, labial scarring, perineum length), speculum exam-
ination (assessment of the vagina, internal hair growth,
granulated tissue, epithelial atrophy, presence of a cervix),
and pelvic examination (accessibility by number of fingers,
vagina length and width (Hegar), strictures, pelvic floor tone,
vaginal discharge). In addition, cosmetic scores (scale 1–
10; 1 = extremely poor, 10 = excellent, <6 was insuﬃcient)
were given by both the gynecologists and patients. The
gynecologists in both institutions had not been previously
involved in the gynecological care of these women.
Data on genital surgeries as well as the degree of viriliza-
tion at birth were retrospectively collected from the medical
files. The degree of genital masculinization in females with
congenital adrenal hyperplasia (CAH) is typically described
according to Prader stages, but in a number of our patients
the Prader stage was not recorded.More recently, the external
masculinisation score (EMS) was developed to assess the
degree of undervirilization in an individual with 46, XYDSD.
The score is based on the presence or absence of a micropenis
and bifid scrotum, the location of the urethral meatus and
the position of the testes [16]. For patients with gonadal
dysgenesis, however, no such classification system has been
developed (yet). Therefore, we developed a categorization
system that could be applied to the entire group of patients:
(1) Patients with 46, XY DSD and Chromosomal (Chrom)
DSDwith normal appearing female external genitalia (46 XY,
NF) (i.e., patients with a normally sized clitoris, normally
developed labia minora and majora, vaginal dysplasia and
gonads in the abdomen or groins (2); patients with 46,
XY DSD and Chromosomal DSD with various degrees of
virilization of the external genitalia (46, XY AG) (i.e., patients
with an enlarged clitoris, partially or completely fused labia,
vaginal dysplasia and gonads in the abdomen or groins
(3); patients with 46, XX DSD with various degrees of
virilization of the external genitalia (46, XXAG) (i.e., patients
with congenital adrenal hyperplasia (CAH)) often born with
ambiguous genitalia such as an enlarged clitoris, partially or
completely fused labia, small introitus, or confluence of the
vagina and urethra (see Table 1).
2.2.2. Psychological Assessment. A sexual dysfunction, ac-
cording to the DSM-IV-TR, is diagnosed by decreased sexual
function and increased sexual distress. Sexual functioning
was assessed by the Female Sexual Function Index (FSFI)
questionnaire [17], validated for the Dutch speaking popula-
tion [18]. This short 19-item quiz assesses adult female sexual
quality of life in the 4-week period before completing the
survey and its score is unbiased regarding age, education, and
economic status. The 19 items are assigned to six separate
domains of female sexual function: desire, arousal, orgasm,
sexual pain, vaginal lubrication, and global sexual and
relationship satisfaction. Since women without partner were
not able to answer items 14 and 15 (relating to relationship
satisfaction), their satisfaction score was solely based on item
16 (relating to global sexual satisfaction). An adjusted total
FSFI score was calculated as well. Sexual distress was assessed
by the Female Sexual Distress Scale-Revised (FSDS-R) [19].
Additionally, a semistructured interview provided in-depth
information about psychosexual and social adjustment. Clin-
ical psychologists in each centre performed the psychosexual
assessments; they had not been involved in the care of these
women.
2.2.3. Statistics. In order to evaluate the cosmetic outcome,
univariate and backwards stepwise linear regression analyses
were used to identify factors associated with cosmetic out-
come. The relationship between continuous parameters and
phenotype/virilization or surgical procedure was analyzed
using the Spearman’s rank order coeﬃcient. Confounding
and eﬀect modification were assessed with stratified back-
wards stepwise linear regression analysis. We looked for a
significant contribution of the interaction eﬀects on the
predictive ability of the model by adding the interaction
eﬀects to the main eﬀects.
Psychosexual functioning in relation to genital viriliza-
tion and genital surgery was assessed by an ANCOVA with
psychosexual outcomes as the dependent variables, genital
surgery (yes/no) and category of virilization as fixed factors,
and number of genital surgeries and age at first surgery
entered as covariates to correct for confounding variables.
Categorical data were analyzed using the χ2 test or Fisher’s
exact test. The SPSS 17.0 software was used for all statistical
calculations. A P value <0.05 was considered statistically
significant. Two-tailed statistical tests were chosen to reduce
the risk of type I errors.
3. Results
Surgery (vaginoplasty and/or clitoroplasty) was performed
in 58/91 (64%) of the women. Details are given in Table 2.
Using the classification based on degree of virilization
at birth, 36/40 (90%) of the patients with 46 XX DSD
(i.e., CAH) had feminizing surgery. Three out of the 4
patients who did not have surgery had the simple virilizing
form. Seven out of 30 (23%) of the patients with 46,
XY/Chrom DSD, and a normal female appearance of the
external genitalia had a vaginoplasty (4/15 with CAIS, 3/7
with complete gonadal dysgenesis). Two of the women with
complete GD had a single-stage surgery (i.e., vaginoplasty
and clitoroplasty). 15/21 (71%) of the patients with 46,
XY/Chrom DSD, and ambiguous external genitalia received
feminizing surgery (9/13 patients with PAIS, 17β3 hydrox-
ysteroid dehydrogenase deficiency, or 17, 20 lyase deficiency
and 6/8 with partial gonadal dysgenesis). The mean age
of first surgery was significantly lower in the group of
females with 46, XX DSD and ambiguous external genitalia
(M = 4.1 years, range 0–19 years) than in the group of
females with 46, XY/Chrom DSD, and ambiguous external
genitalia (M = 12.9 years, range 0–27 years) or group of
females with 46, XY/Chrom DSD with a normal female
appearance of the external genitalia (M = 17 years, range
0–28 years) (P = 0.001). The total number of genital
surgeries was also higher in the group of females with
46, XX DSD and ambiguous external genitalia (median 2,
range 0–4), than the group with 46, XY/Chrom DSD and
ambiguous external genitalia (median 1, range 0–4) or 46,
XY/Chrom DSD NF (median 0, range 0–2) (P < 0.001).
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Table 3: Cosmetic outcome score [1–10] based on four aspects of
the external genitalia.
Mean Sd
Clitoris (n = 63) Gynecologist 7.16 1.94
Patient 6.76 1.89
Labia majora
(n = 66)
Gynecologist 7.65 1.60
Patient 7.11 1.48
Labia minora
(n = 64)
Gynecologist 7.28 1.97
Patient 6.73 1.81
Vagina (n = 60) Gynecologist 7.32 1.79
25/91 patients had undergone a clitoroplasty in childhood, of
them 10 underwent a vaginoplasty and 11 an introitusplasty
in puberty. Another 20 patients had undergone a genitoplasty
planned as single stage. 7 of them needed a revaginoplasty
and 5 a Reintroitusplasty because of vaginal insuﬃciency
(see Table 2). 30/51 women who had a vaginoplasty (with
or without concurrent clitoroplasty) had to follow a home
routine dilation programme after surgery to maintain their
vaginal length or introitus width (when having no regular
sexual intercourse). 14/51 women did not have to do this,
and in 7 women this information was missing. Of the
33/91 women who had no feminizing surgery, 9 women
followed a vaginal dilation programme to create suﬃcient
vaginal length. The other 24 women had no medical genital
treatment.
Eight women (17%) of the women experienced some
urinary incontinence (urge, stress, or both), of them seven
had undergone surgery, and one had not.
3.1. Cosmetic Outcome. A third of the patients refused to take
part in the gynecological checkup. Reasons for refusal were
related to time pressure but more often having undergone
examinations of the genitalia that had been experienced as
shameful.
The cosmetic outcomes scores, given by both patients
and gynecologists, are summarized in Table 3. Gynecologists
scored the appearance of the genitalia on average higher
than the patients. For the clitoris and labia majora, scores
of patients and gynecologists did not diﬀer (P > 0.05);
for the labia minora scores were diﬀerent (P = 0.013).
No comparison for the vagina could be made, since only
gynecologists rated this aspect of the genitalia.
A satisfactory cosmetic outcome, defined as a mean
gynecologic score above 6, was present in all the diagnostic
groups (M = 7.4, sd = 1.4). Women who had undergone
surgery had on average lower cosmetic scores than women
who did not have any surgery (M = 7.0, sd = 1.25 versus
M = 8.2, sd = 1.37) (P = 0.000) (Table 4), but this diﬀerence
disappeared when corrected for the virilization degree at
birth, total number of surgeries, and age at first surgery
(P = 0.073, ns). Age at first surgery and total numbers
of surgeries were significantly associated with the cosmetic
outcome score (r = 0.421, P = 0.005 and r = −0.441,
P < 0.001, resp.), indicating that a lower cosmetic outcome
was associated with a younger age at first surgery and a higher
number of undergone surgeries. Regression analysis showed
that only the level of virilization had a significant eﬀect on
the cosmetic outcome score (P = 0.022), after correction
for number of surgeries and the interaction eﬀects of surgery
with virilization. The adjusted R2 of this model was 0.217.
To see whether age at first surgery contributed to the
cosmetic outcome score we performed a regression analysis
on the group that was operated. After correction for number
of surgeries, degree of virilization, and the interaction eﬀects
of age at first surgery and degree of virilization, there was
no significant contribution of the age at first surgery on the
cosmetic outcome (P = 0.113). The adjustedR2 of this model
was 0.173.
3.2. Psychosexual Outcome. 8 women did not want to fill
in the FSFI because they did not want to answer in details
questions about their sexuality. Of the other 83 women, 25
women (30%) were not sexually active in the 4-week period
before taking part in the study. A variety of reasons was
reported, ranging from having no time or no need for sex, to
a problematic confrontation with the body and diagnosis. An
extra 15 women specifically did not have sexual intercourse.
In fact, 41% (32/79) never had sexual intercourse at the
moment of follow-up (10 women did not have had surgery,
22 had had surgery). Those who never had sexual intercourse
were on average younger (median 18 years, range 14–46
years) than those who had intercourse (median 23 years,
range 19–48 years) (P = 0.034). The in-depth interview
revealed that reasons for virginity mostly related to age (i.e.,
considering themselves too young), sexual orientation (some
women with CAH and PAIS only had sexual experiences in
lesbian relationships), and considering their bodies unsuit-
able for having intercourse (i.e., vagina was too narrow,
although this was anatomically not confirmed).
The original total FSFI score was only known in 35
women, because of the missing values on the domains
of satisfaction and pain. 40% (36/85, in 6 women this
information was missing) of the women had no (sexual)
partner. 66% of the women (23/35) with a total FSFI score
scored below the clinical cut-oﬀ of 26.55 on the FSFI,
which indicates that they are at risk for developing a sexual
dysfunction.
An adjusted total FSFI score was calculated because of the
above-mentioned drawbacks with the FSFI. In 22 patients
with no partner, the satisfaction domain was solely based
on one item. In the other patients without partner, no data
on satisfaction were available and the FSFI score could not
be calculated for them. This problem was reported before
by Meyer-Bahlburg and Dolezal [20]. A similar problem was
seen with items in the pain domain, resulting in a pain score
based on 2 items instead of 3. An adjusted FSFI score, with
only adjusted satisfaction and pain scores, was then known
in 60/91 patients.
The total FSDS-R score was known in 76 women. In 41%
(31/76) of these women, the FSDS score is above the clinical
cut-oﬀ score of 11, indicating that they experience sexuality-
related distress.
No significant diﬀerences were found between women
with and without surgery on the total FSFI, adjusted FSFI,
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Table 4: Univariate analysis of cosmetic and psychosexual outcomes in the surgery—no surgery group. Only cosmetic outcome was
significantly diﬀerent in the surgery versus non surgery group (P < 0.001).
Cosmetic outcome FSDS FSFI Adjusted FSFI
SURGERY Mean Sd N Mean Sd N Mean Sd N Mean Sd N
No surgery 8.21 1,37 25 10.23 10,4 25 20.71 10,16 15 21.67 9.35 23
Surgery 6.97 1,25 45 11.00 9,62 51 22.17 9,4 20 20.95 10.1 41
0
1
2
3
4
5
6
Desire Arousal Lubrication Orgasm Satisfaction Pain
FSFI domains
No surgery
Surgery
(±
1.
0)
(±
1.
3)
( ±
2.
1)
(±
2.
3)
( ±
2.
3)
(±
2.
6)
(±
2.
2)
(±
2.
6)
(±
1.
4)
(±
1.
2)
( ±
2.
4)
(±
2.
3)
Figure 1: Mean scores (±sd) on the six domains of the Female Sex-
ual Function Index (0–6) in women with and without feminizing
surgery.
and FSDS (Table 4), nor on the diﬀerent FSFI domains,
expect for the satisfaction domain (Figure 1). Women who
had surgery were more satisfied with their sexual life than
women without surgery (P = 0.037). However, when
the adjusted satisfaction score was used, this diﬀerence
disappeared. No significant diﬀerences were found between
women who had surgery and those who had not on the
total FSFI (original, adjusted) (P = 0.395 and P = 0.455,
ns), nor on the diﬀerent FSFI domains when corrected for
the number of surgeries, level of virilization, and age at
first surgery. Also no significant diﬀerence was found when
the same model was tested with the FSDS-R as dependent
variable (P = 0.078, ns). No significant associations were
found between age at first surgery, total number of surgeries,
and virilization degree on the one hand and total FSFI and
FSDS on the other hand.
4. Discussion
Clinical practice developed to promote psychological and
sexual health in DSD is the subject of current critical review.
The role of genital surgery, in particular, is under intense
scrutiny. Crucial to the debate on the role of surgery are
conflicting empirical long-term outcome data.
The results of this study show that, while cosmetic out-
comes are suﬃcient, a large proportion of the patients suﬀer
from psychosexual diﬃculties. 40% experienced sexuality-
related distress and 66% of the sample was at risk for devel-
oping a sexual dysfunction. However, no major influence of
genital surgery on cosmetic and psychosexual outcomes was
found.
Recognizing the diﬃculty of accurate assessment, our
study suggests that surgery does not seem to improve sexual
satisfaction. On the other hand, there is no evidence that
feminizing surgery has worsened psychosocial outcomes.
Those patients with the highest degrees of genital ambiguity
might actually have benefitted from surgery, as their scores
on sexual functioning were at the same level as those women
with DSD with less severe virilization of the external genita-
lia. This observation, however, is not in line with those found
in previous studies [21].
There are isolated reports of successful psychosexual out-
come in adult females with ambiguous genitalia, but their
numbers are unclear and their case histories have not
been well documented [22]. Although heavily influenced by
cultural and ethnic issues, observations made by Warne (not
published) in India and Vietnam and our own observations
in Indonesia suggest that most individuals who grow up with
ambiguous genitalia—because surgery was not available—
are suﬀering from social stigmatization on a daily basis.
However, altered genital sensation and inability to
achieve orgasm were reported after clitoroplasty in some
series [13, 21, 23–25], even with the use of modern surgical
techniques to preserve clitoral sensation, but not in others
[26]. While older studies, looking at psychosexual func-
tion after vaginoplasty, reported reasonable outcomes [27],
subsequent studies have shown both positive and negative
eﬀects on sexual development and activity [28]. Some
reported a high incidence of sexual dysfunction, especially
in CAH women with higher virilization grades [7, 21, 29].
Although long-term cosmetic outcomes are average to good
(assessed by gynecologists), resurgery for complications such
as vaginal stenosis or fistula’s are common [30]. Creighton
et al. [31] found that 98% needed further treatment of
the vagina for tampon use or intercourse. This was also
confirmed in our study, where in 60% resurgery in puberty
was needed after an initial single-stage procedure because of
a narrow introitus and/or for more extensive reconstruction
because of vaginal insuﬃciency.
When feminizing surgery is performed in cases of an
absent or short vagina, such as in complete androgen insensi-
tivity syndrome, the first line of treatment should be vaginal
dilators [32, 33] due to the absence of surgical risk and
preservation of vaginal tissue. In the past, surgical methods
6 ISRN Endocrinology
were the cornerstone of treatment, although postoperative
vaginal dilation still had to be performed. In this sample,
68% of the women had to dilate after surgery. Available stud-
ies on primary vaginal dilation programmes claim success
rates in the region of 80% [34–36]. 9 out of 91 women in
our sample followed a primary vaginal dilation programme.
Since this group was rather small, no definite conclusions
could be reached in terms of sexual functioning, especially
compared to vaginal surgery. Most studies investigating
sexual function after (diﬀerent procedures of) vaginoplasty,
however, agree that women with vaginal hypo- or aplasia are
at risk for developing sexual problems (diﬃcult lubrication,
inability to experience orgasm, and dyspareunia), despite
treatment [37–41], with both psychological and physical
factors probably predisposing for sexual diﬃculties.
Currently most clinicians consider that childhood genital
surgery is indicated in those with a higher degree of genital
ambiguity to avoid the assumed psychological distress of
passing through childhood and adolescence with abnormal
looking genitalia [1]. However, it has been suggested that a
vagina is not necessary for a young girl prior to menarche
or sexual intercourse. This was confirmed by women with
complete absence of the vagina (e.g., CAIS), who indicated
no psychological or developmental problems until they
experienced primary amenorrhea. It would seem logical then
to defer vaginal surgery until later in life (although this is
explicitly not in agreement with the consensus statement
[1]). This should also limit the total number of operations
an individual will undergo and allow for the patient to
consent and to be involved in the decision for surgery [5].
Moreover, since the risk of stenosis is high after prepubertal
vaginoplasty and moderate clitoral hypertrophy may regress
with medical therapy for CAH, other surgery such as
vaginoplasty may be delayed [42]. On the other hand, when
a clitoroplasty is indicated for severe clitoral hypertrophy, the
redundant clitoral skin can be used for a vaginoplasty in the
same procedure.
Our results did not indicate that the number of surgeries
performed or the age at first surgery were associated with
a better cosmetic outcome. As was also shown in our study
and highlighted by Alizai et al. [28], total correction cannot
always be achieved with a single operation in infancy. On
the other hand, while the evidence that feminizing surgery
will improve psychological outcomes is lacking, there are
objective reasons why patients being treated with genital
surgery now should expect a better outcome than patients
treated 20–30 years ago. Clitoral surgery has improved,
in addition to counseling methods [22]. It is becoming
increasingly clear that one of the most important factors
determining the success of operations such as vaginoplasty
is the psychological coping of the patient [43].
A large proportion of the women in the semistructured
interview mentioned the struggles to cope with their diagno-
sis, reinforced by societies’ ignorance of DSD conditions and
general taboos over sexual issues. Some of them described
the loss of a sense of normality and equality with peers
and the impossibility of communication about it. Especially
the distress caused by infertility seemed to leave some of
these women inferior to others. This self-perception may
negatively aﬀect a person’s sexual esteem and behavior
and lead to sexual diﬃculties [8]. Another explanation for
the high degree of psychosexual distress and dysfunction
reported is a sort of self-fulfilling prophecy, where the women
might have felt that sexual diﬃculties were to be expected
and reported accordingly. In contrast, satisfaction levels were
not very low, indicating that perhaps the women were not
dissatisfied with the low expectations of sexual functioning,
precisely because they were to be expected [8].
We recognize several weaknesses of this study. Firstly, it
was diﬃcult to precisely quantify the degree of virilization
due to the heterogeneity of DSD diagnoses, and thus diﬀerent
underlying virilization mechanisms. A variety of techniques
had to be used to assess the virilization degree and the
classification system we used has not been described before.
Secondly, there was a potential selection bias, since partici-
pants in this study were recruited exclusively from a clinical
sample. Possibly, women who opted into the study were
those who had reached a stage of acceptance and felt able to
talk about their experiences. Alternatively, clinically recruited
patients may have a higher incidence of complications,
including sexual diﬃculties, and a call to take part in a study
may have prompted them to seek medical advice [8]. Further
studies should also recruit from other samples, such as peer-
support groups. Additionally, data on nonresponders should
be gathered. Half of the women who have been tracked
refused to participate, indicating that physical aspects of
female sexuality are still a very sensitive subject. Secondly,
we were unable suﬃciently to check some factors other than
surgery that may aﬀect sexual function. Other presumed
factors such as the social stigma attached to having a DSD,
diagnostic secrecy practiced by some clinicians, and other
unresolved psychological issues and anxieties related to living
with this condition need to be further explored. Lastly, this
was a retrospective follow-up study and no information
was available on psychosexual and social functioning before
treatment. Prospective, longitudinal studies with a focus on
diagnosis-related success rates should be undertaken.
5. Conclusions
Feminizing genitoplasty procedures have changed dramat-
ically since the 1980s, but still there is no consensus and
there are few long-term data on which to base the decision of
the timing on genital surgery. One of the major problems is
our knowledge of the parameters determining “sexual quality
of life.” Endocrine factors are probably as important as the
genetic factors, the environmental, cultural, and educational
ones, to establish a sexual profile [44]. Every woman with
DSD should, therefore, be referred to a multidisciplinary
team, integrating endocrinology, sexology, and gynecology
expertise. Clinical psychological support should be available
in an ongoing matter into adulthood, as psychological
aspects of living with a DSD condition impact in many areas
of life. Any surgery oﬀered, including vaginoplasty, clitoral
surgery, and gonadectomy should be presented with full
information on both the potential benefits and the risks of
the procedure.
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